Kairos Pharma (NYSEAMERICAN:KAPA) Trading Down 4.7% – Should You Sell?

Kairos Pharma, Ltd. (NYSEAMERICAN:KAPA)’s share price fell 4.7% on Thursday . The company traded as low as $0.2695 and last traded at $0.2979. 1,613,029 shares changed hands during trading, a decline of 73% from the average session volume of 5,891,854 shares. The stock had previously closed at $0.3127.

Kairos Pharma Stock Performance

The company has a market cap of $6.38 million, a PE ratio of -0.99 and a beta of 1.50. The company’s 50 day moving average price is $0.42 and its 200-day moving average price is $0.56.

Kairos Pharma (NYSEAMERICAN:KAPA) last posted its quarterly earnings data on Wednesday, May 13th. The company reported ($0.08) EPS for the quarter. Equities research analysts expect that Kairos Pharma, Ltd. will post -0.37 EPS for the current year.

Institutional Inflows and Outflows

A hedge fund recently bought a new position in Kairos Pharma stock. XTX Topco Ltd acquired a new stake in Kairos Pharma, Ltd. (NYSEAMERICAN:KAPA) during the second quarter, according to its most recent 13F filing with the SEC. The fund acquired 62,746 shares of the company’s stock, valued at approximately $44,000. XTX Topco Ltd owned 0.31% of Kairos Pharma as of its most recent filing with the SEC.

About Kairos Pharma

Kairos Pharma (NYSEAMERICAN:KAPA) is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapies to treat genetic diseases caused by nonsense mutations. The company’s proprietary platform leverages targeted ribosomal modulation to promote readthrough of premature stop codons, with the goal of restoring production of full‐length functional proteins. Kairos Pharma’s pipeline includes multiple programs in preclinical and early clinical development for rare pediatric and orphan indications.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Kairos Pharma brings together a multidisciplinary team of researchers and clinicians dedicated to translating its technology into potential therapeutics.